A rational approach to the treatment of bronchial asthma in children: what can we do to control the disease?

Bronchial asthma is the most common among chronic bronchopulmonary diseases with heterogeneity in symptom profiles. Despite the delivery of baseline anti-inflammatory iGCS therapy, including the subsequent staged addition of other controlling treatment methods, symptoms of the disease persist in 40% of patients. Lack of asthma control results in high morbidity, mortality and treatment costs, which justifies the search for new therapeutic options to improve control and reduce the risk of future exacerbations. Tiotropium, a long-acting anticholinergic bronchodilator, can be a good alternative in the therapeutic treatment of poorly controlled asthma in both adults and children. Several clinical studies showed the efficacy and safety of Tiotropium Respimat Soft Mist Inhaler at a dose of 5 mg in various asthma treatment options in children at 6 years old and over, who do not achieve asthma control with iGCS monotherapy at medium/high doses or with iGCS/LABA combination at medium/high doses. All asthma studies in children were conducted using Respimat Soft Mist Inhalers that generate an aerosol with a larger number of small particles, which ensures effective drug distribution and deposition in the lungs. The aerosol cloud velocity at the nozzle outlet of the inhaler is just 0.8 m/s, and the time period over which the aerosol is released is extended to 1.5 s. Moving slowly, aerosol particles more often avoid colliding with the posterior pharyngeal wall and tongue, which reduces the drug deposition in the oral cavity, significantly increasing the amount of active substance delivered to the air ways. 55% of the dose of tiotropium bromide is released in the form of particles with an optimal aerodynamic diameter, which guarantees a high level of lung deposition - 52% of the ex-valve dose.

1. ReddeL H.K., Pedersen S. (eds.). Global Strategy for Asthma Management and Prevention. 2018. Available at: https://ginasthma.org/wp-content/ upLoads/2019/01/2018-GINA.pdf.

2. ChuchaLin A.G., Geppe N.A., KoLosova N.G., Kondyurina E.G., MaLakhov A.B., Mizernitskiy Yu.L., Revyakina V.A. (eds.) National program: Bronchial Asthma in Children. Treatment Strategy and Prevention. Moscow: OriginaL-maket; 2017. 160 p. (In Russ.). AvaiLabLe at: http//astgmu.ru/ wp-content/upLoads/2018/10/NatsionaLnaya-programma-BA-u-detej.-Strategiya-Lecheniya-i-profiLaktika.pdf.

3. Morandi L., BeLLini F., Papi A. Asthma: definition, severity and impact of puLmonary exacerbations. In: BurgeL P.-R., ContoLi M., Lopez-Campos J.L. (eds.) Acute Exacerbations of Pulmonary Diseases (ERS Monograph). SheffieLd, European Respiratory Society; 2017. pp. 1-12.

4. Nunes C., Pereira A.M., Morais-ALmeida M. Asthma costs and sociaL impact. Asthma Res Pract. 2017;3(1). AvaiLabLe at: https://asthmarp.biomedcentraL.com/articLes/10.1186/s40733-016-0029-3.

5. Winer R.A., Oin X., Harrington T., Harrington T., Moorman J., Zahran H. Asthma Incidence among ChiLdren and AduLts: Findings from the BehavioraL Risk Factor SurveiLLance System Asthma CaLL-back Survey - United States, 2006-2008. J Asthma. 2012;49(1):16-22. doi: 10.3109/02770903.2011.637594.

6. Chung K.F., WenzeL S.E., Brozek J.L., Bush A., Castro M., Sterk P. J. et aL. InternationaL ERS/ATS guideLines on definition, evaLuation and treatment of severe asthma. Eur Respir J. 2014;43:343-373. doi: 10.1183/09031936.00202013.

7. Custovic A., Johnston S.L., Pavord I., Gaga M., Fabbri L., BeL E.H. et aL. EAACI position statement on asthma exacerbations and severe asthma. Allergy. 2013;68(12):1520-1531. doi: 10.1111/aLL12275.

8. Johnston N.W., Sears M.R. Asthma exacerbations 1: EpidemioLogy. Thorax. 2006;61:722-728. doi: 10.1136/thx.2005.045161.

9. Bateman E.D., ReddeL H.K., Eriksson G., Peterson S., OstLund O., Sears M.R. et aL. OveraLL asthma controL: The reLationship between current controL and future risk. J Allergy Clin Immunol. 2010;(3):125:600-608.e6. doi: 10.1016/j.jaci.2009.11.033.

10. Bateman E.D., Bousquet J., Busse W.W., CLark TJ.H., GuL N., Gibbs M. et aL. StabiLity of asthma controL with reguLar treatment: an anaLysis of the Gaining OptimaL Asthma controL (GOAL) study. Allergy. 2008;63(7):932-938. doi: 10.1111/j.1398-9995.2008.01724.x.

11. Barnes PJ. Tiotropium bromide. Expert Opin Investig Drugs. 2001;10(4):733-740. doi: 10.1517/13543784.10.4.733.

12. Kerstjens H.A., EngeL M., DahL R., Paggiaro P., Beck E., VandewaLker M. et aL. Tiotropium in Asthma PoorLy ControLLed with Standard Combination Therapy. N Engl J Med. 2012;367:1198-1207. doi: 10.1056/NEJMoa1208606.

13. Scott G.D., Fryer A.D. RoLe of Parasympathetic Nerves and Muscarinic Receptors in ALLergy and Asthma. Chem Immunol Allergy. 2012;98:48-69. doi:10.1159/000336498.

14. Ouizon A., CoLin A.A., PeLosi U., Rossi G.A. Treatment of disorders characterized by reversibLe airway obstruction in chiLdhood: are antichoLinergic agents the answer? Curr Pharm Des. 2012;18(21):3061-3085. doi: 10.2174/1381612811209023061.

15. Ouirce S., Dominguez Ortega J., Barranco P AntichoLinergics for treatment of asthma. J Investig Allergol Clin Immunol. 2015;25(2):84-93. AvaiLabLe at: https//www.ncbi.nLm.nih.gov/pubmed/25997301.

16. BueLs K.S., Fryer A.D. Muscarinic Receptor Antagonists: Effects on PuLmonary Function. Handbook Exp Pharmacol. 2012;208:317-341. doi: 10.1007/978-3-642-23274-9_14.

17. VogeLberg C., Moroni-Zentgraf P, Leonaviciute-KLimantaviciene M., Sigmund R., HameLmann E., EngeL M., SzefLer S. A randomised dose-ranging study of tiotropium Respimat in chiLdren with symptomatic asthma despite inhaLed corticosteroids. Respir Res. 2015;16:20. doi: 10.1186/s12931-015-0175-9.

18. Bickmann D., Kamin W., Sharma A., WachteL H., Moroni-Zentgraf P., ZieLen S. In Vitro Determination of Respimat Dose DeLivery in ChiLdren: An EvaLuation Based on InhaLation FLow ProfiLes and Mouth-Throat-ModeLs. J Aerosol Med Pulm Drug Deliv. 2016;29(1):76-85. doi: 10.1089/jamp.2014.1166.

19. Kamin W., Frank M., Kattenbeck S., Moroni-Zentgraf P, WachteL H., ZieLen S. A HandLing Study to Assess Use of the Respimat Soft Mist™ InhaLer in ChiLdren Under 5 Years OLd. J Aerosol Med Pulm Drug Deliv. 2015;28(5):372-381. doi: 10.1089/jamp.2014.1159.

20. Geppe N.A., KoLosova N.G., Arkhipov V.V., Mizernitskiy Yu.L., BLokhin B.M., Bashkina O.A. et aL. The use of tiotropium in basic therapy of bronchiaL asthma in chiLdren. ConcLusion of the Expert CounciL of the Paediatric Respiratory Society. Voprosy prakticheskoy pediatrii = Clinical Practice in Pediatrics. 2017;12(4):77-84. (In Russ.) AvaiLabLe at: http://www.phdynasty.ru/kataLog/zhurnaLy/voprosy-prakticheskoy-pedi-atrii/2017/tom-12-nomer-4/31631.

21. VogeLberg С. Emerging roLe of Long-acting antichoLinergics in chiLdren with asthma. Current Opinion in Pulmonary Medicine. 2016;22(1):74-79. doi: 10.1097/mcp.0000000000000229.